GlassScriptPhysician profile
Sara Moghaddam
NPI 1013203462
$11,582.54
in general payments reported to CMS, 2019-2025
33 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,053 · 2020: $1,436 · 2021: $1,682 · 2022: $1,211 · 2023: $2,118 · 2024: $1,710 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,200.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,464.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,625.95 | 2019-2024 | |
| Genzyme Corporation | $902.92 | 2019-2025 | |
| Janssen Biotech, INC. | $863.13 | 2022-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $717.96 | 2019-2024 | Taltz, Zepbound, Olumiant |
| Galderma Laboratories, L.P. | $655.58 | 2019-2025 | Nemluvio, Dysport |
| Regeneron Healthcare Solutions, INC. | $546.29 | 2019-2025 | Dupixent, Libtayo |
| Biofrontera INC. | $447.78 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $376.47 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Organogenesis INC. | $349.89 | 2023-2025 | Via Matrix, Puraply, Nushield |
| Genentech USA, INC. | $290.19 | 2019-2023 | Erivedge |
| Leo Pharma INC. | $262.77 | 2021-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.73 | 2022-2024 | Spevigo |
| Amgen INC. | $260.67 | 2019-2024 | Otezla |
| Pfizer INC. | $226.52 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $180.47 | 2022-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $158.06 | 2020-2021 | |
| Celgene Corporation | $132.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $126.38 | 2019-2021 | |
| Sensus Healthcare, INC. | $87.34 | 2024 | |
| Hill Dermaceuticals, INC. | $72.66 | 2022 | |
| Incyte Corporation | $65.81 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $59.59 | 2023 | |
| Kerecis Limited | $42.65 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Almirall LLC | $41.89 | 2021 | |
| Janssen Scientific Affairs, LLC | $37.62 | 2023 | Tremfya |
| Mallinckrodt Hospital Products INC. | $35.41 | 2024 | Acthar |
| Merck Sharp & Dohme LLC | $28.01 | 2020 | |
| Dusa Pharmaceuticals, INC. | $23.53 | 2019 | |
| Dermavant Sciences, INC. | $22.38 | 2023 | Vtama |
| Mission Pharmacal Company | $21.10 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Moghaddam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.